The collaboration contributes to climate commitments Neste made in 2020, including a commitment to reduce and compensate emissions from its employees’ business travel through the use of the company’s own sustainable aviation fuel.
…
…
Neste and NuStar Energy are also teaming up on supplying SAF to California airports. Supply trucks are now able to load Neste MY Sustainable Aviation Fuel at the NuStar-operated Selby Terminal near San Francisco, California. The first gallons have been safely picked up and delivered to the nearby Monterey Regional Airport. Due to the strategic location of the Selby Terminal, Neste and its partners Avfuel and Signature Flight Support are now able to supply sustainable aviation fuel to a growing number of airports across the western United States. In 2020, Neste established a continuous supply of SAF to San Francisco International Airport from NuStar’s Selby Terminal using an existing pipeline – a first for the industry.
There were 22 weekdays in April. There were 15 announcements about sustainable aviation fuel progress, advancements, implementations, and production in just those 21 days. What does that mean? Why is SAF suddenly taking off like never before, even as the aviation industry was turned upside down due to the COVID-19 pandemic? Why are companies pivoting from other fuels to focus on SAF?
In today’s Digest, let’s kick the tires and light the fires as SAF is cleared for take-off. The latest SAF news and what it means.
Neste’s News
Let’s start with the most recent big news that Neste will convert up to 500,000 tons of its existing renewables production capacity at Rotterdam refinery for SAF. Currently the refinery produces mainly Neste MY Renewable Diesel. The modifications to the refinery, an investment of approximately EUR 190 million, will enable Neste to optionally produce up to 500,000 tons of SAF per annum as part of the existing capacity.
Home > Press > Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Abstract: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the companys second generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited ( Takeda) as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). The results demonstrate that ARO-AAT treatment led to a consistent and substantial reduction in intra-hepatic mutant AAT protein (Z-AAT), both Z-AAT monomer and Z-AAT polymer; a consistent decrease in histological globule burden; improvements in fibrosis; and, improvements in other relevant biomarkers of liver health. Arrowhead intends to present additional interim AROAAT2002 data at an upcoming medical congress
Novavax COVID-19 Vaccine (NVX-CoV2373) Description
Novavax COVID-19 vaccine (NVX-CoV2373) (Covovax) is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies.
Novavax Inc. s NVX-CoV2373 vaccine candidate creates an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The baculovirus then infects a culture of Sf9 moth cells, which create the spike protein and display it on their cell membranes. The spike proteins are then harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins.
Published: Apr 28, 2021
Both Awards, Issued by the International Society for Pharmaceutical Engineering (ISPE), Underscore Takeda’s Leadership in Digital and Innovative Technologies
New Solid Pharmaceutical Packaging Building With Automatic Line Clearance in Hikari, Japan, Wins Process Intelligence and Innovation Award
End-to-End High Potent Drug Facility in Grange Castle, Ireland, Is Recognized as Category Winner for Facility Integration
(TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. Takeda’s new solid pharmaceutical packaging building in Hikari, Japan, was recognized with the 2021 “Process Intelligence and Innovation” category award. Additionally, the end-to-end high potent drug facility in Grange Castle, Ireland, was selected as “Facility Integration” category winner.